Contract R&D and Manufacturing Organization-Speed up development & market launching by specialized CRMO Service

Product

  • Products >
  • Product

EcML®

EcML®
EcML®
Product Name Monophosphoryl lipid A from recombinant E.coli
Use Immunostimulant, Vaccine adjuvant
Q&A
  • * E.coli engineering to directly produce Monophosphoryl Lipid A
  • * Similar structure with MPLA from salmonella, Synthetic MPLA(GLA)
  • * Simple manufacturing process, higher yield, lower manufacturing cost
  • * Hexa acyl MLA ≥50 %
Monophosphoryl Lipid A(MLA) is basically used as a vaccine adjuvant. Adjuvants are added to vaccine to enhance immune response to produce more antibodies and long-term protection. Moreover, adjuvants can reduce the amount of antigen. MLA directly activates APC(Antigen Presenting Cell) expressing TLR-4, stimulating the production of cytokines and co-stimulatory molecules. MLA is well-known as novel adjuvant and is manufactured by only a few companies.
Its potential is expanded to a variety of indication such as allergy, cancer(with checkpoint inhibitor), Alzheimer’s disease and other immune response.

Formulation

1.0mg, 5.0mg/vial

Storage temperature

2℃~8℃

Contact

For larger quantities, pricing
information and inquiries for custom products,
please email sales@eubiologics.com

Shelf life

12 months